<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03110679</url>
  </required_header>
  <id_info>
    <org_study_id>OA-bi-Blind</org_study_id>
    <nct_id>NCT03110679</nct_id>
  </id_info>
  <brief_title>Randomized Double-blind Study on the Treatment of Osteoarthritis of the Bilateral Knee: Autologous Bone Marrow Concentrate vs. Hyaluronic Acid</brief_title>
  <acronym>OA-bi-Blind</acronym>
  <official_title>Randomized Double-blind Study on the Treatment of Osteoarthritis of the Bilateral Knee: Autologous Bone Marrow Concentrate vs. Hyaluronic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OA-bi-Blind is a randomized double-blind study on the treatment of osteoarthritis of the
      Bilateral knee: autologous bone marrow concentrate vs. hyaluronic acid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      a randomized, controlled, double-blind study and we will be evaluated and compared the
      clinical and radiological results of concentrated autologous bone marrow against the
      hyaluronic acid in patients with bilateral knee osteoarthrosis . In randomization, one knee
      will be treated with autologous bone marrow concentrate and other knee with hyaluronic acid,
      then every patient is considered both in control and treatment group, limiting the
      heterogenity between groups and will not be informed of the knee assigned to the treatment
      group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2016</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>autologous bone marrow concentrate vs. hyaluronic acid.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>cover the syringe to mask the contents</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>International Knee Documentation Committee (IKDC)-Subjective score</measure>
    <time_frame>Time Frame: 6 months</time_frame>
    <description>Clinical improvement, measured by the change in scores IKDC Subjective</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Knee Documentation Committee (IKDC)-Subjective score</measure>
    <time_frame>Time Frame: 1,3,6, 12, 24 months evaluation</time_frame>
    <description>Stability of the initial clinical improvement between 6 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthitis Outcome Score (KOOS).</measure>
    <time_frame>Time Frame: 1,3,6, 12, 24 months evaluation</time_frame>
    <description>Stability of the initial clinical improvement between 6 and 24 months of the KOOS pain score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>autologous bone marrow concentrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concentration of bone marrow taken from the patient's right tibia using Bio-MAC® suction catheter, company Biologic Therapies, Inc., and concentrated by centrifuge Bio.SPINTM Magellan®, company Biologic Therapies , Inc., and its injection in the intra-articular.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hyaluronic acid.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single injection of intra-articular hyaluronic acid 60mg (4 cc), and serve as a control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>injection of autologous bone marrow concentrate</intervention_name>
    <arm_group_label>autologous bone marrow concentrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>injection of hyaluronic acid.</intervention_name>
    <arm_group_label>hyaluronic acid.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients, aged between 18 and 75 years;

          2. Bilateral symptomatic knee osteoarthritis (Kellgren-Lawrence grade 1-4);

          3. Failure after two months of conservative treatment;

          4. Capacity and consent of patients to participate actively in the rehabilitation
             protocol, follow-up clinic and radiology protocol;

          5. Signature of informed consent.

        Exclusion Criteria:

          1. Patients incapable of discernment;

          2. Patients with malignancy

          3. Patients with rheumatic diseases;

          4. Patients with diabetes;

          5. Patients with metabolic disorders of the thyroid;

          6. Patients belonging abuse of alcohol, drugs or medications;

          7. Patients with misalignment of the lower limbs than 10 °;

          8. Body Mass Index&gt; 40;

          9. Patients with a history of trauma or intra-articular infiltration of therapeutic
             substances within 6 months prior to treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rizzoli Orthopaedic Institute</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizaveta Kon, MD</last_name>
      <phone>0516366567</phone>
      <email>e.kon@biomec.ior.it</email>
    </contact>
    <contact_backup>
      <last_name>Giuseppe Filardo, MD</last_name>
      <phone>0516366501</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Ortopedico Rizzoli</investigator_affiliation>
    <investigator_full_name>Federica Balboni</investigator_full_name>
    <investigator_title>Sub-Investigator</investigator_title>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>autologous bone marrow concentrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

